반응식
[C:1]([N:4]1[CH:8]([C:9]([OH:11])=[O:10])[CH2:7][S:6][CH:5]1[C:12]1[CH:17]=[C:16]([O:18][C:19](=[O:21])[CH3:20])[CH:15]=[CH:14][C:13]=1[O:22][C:23](=[O:25])[CH3:24])(=[O:3])[CH3:2].Cl.N[C@H:28](C(O)=O)CS>>[CH3:28][O:10][C:9]([CH:8]1[CH2:7][S:6][CH:5]([C:12]2[CH:17]=[C:16]([O:18][C:19](=[O:21])[CH3:20])[CH:15]=[CH:14][C:13]=2[O:22][C:23](=[O:25])[CH3:24])[N:4]1[C:1](=[O:3])[CH3:2])=[O:11]참가 물질
3
실험 절차
The procedure described above for preparation of 3-acetyl-2-(2,5-diacetyloxyphenyl)-1,3-thiazolidine-4-carboxylic acid (5) was followed to prepare 10, except that a 2,5-dimethyl ester of L-cysteine hydrochloride was employed as starting material.
후처리
- customto prepare 10
출처 및 근거
- ORD 기록
- ord-b6fe2d06890649408413c427eef63a4f
- 출처 데이터셋
- uspto-grants-2002_03
- 특허 번호
- US06355661B1
연결된 노트
불러오는 중…